Simon Thelwall-Jones appointed as CFO
www.hyjliao.comÎçÒ¹¾ç³¡ Press Release – 23 November 2023
ÎçÒ¹¾ç³¡ bolsters Board & Executive Team with the appointment of Simon Thelwall-Jones as Chief Financial Officer.
In line with the company growth strategy and planned capital raise in 2024, ÎçÒ¹¾ç³¡ is delighted to announce the appointment of Simon Thelwall-Jones as Chief Financial Officer. This appointment greatly strengthens ÎçÒ¹¾ç³¡s financial strategic leadership to deliver on the company’s next major investment milestone. Simon has extensive Corporate & Strategic Finance experience, having held a number of Board level positions, as well as having been Head of Global Strategy and M&A for a $2bn turnover plc. During his career, he has also successfully run a number of large £100m+ investment portfolios, and has been a successful entrepreneur, having built, scaled and exited several businesses.
Said Simon Thelwall-Jones, “I have known of ÎçÒ¹¾ç³¡ for some years and have been impressed with their journey to date. The company is in an extremely exciting growth phase in a market that is rapidly expanding global market and we intend to take advantage of our skill set and product offering in a niche sector of the food allergy market.â€
Dr. Paul Abrahams, CEO of ÎçÒ¹¾ç³¡ said. “Simon is a critical appointment for ÎçÒ¹¾ç³¡ at this stage of our lifecycle and he will be instrumental in our growth strategy moving forward. His wealth of experience will be invaluable in supporting the rest of the senior management team and to bolster the board as we embark on a capital raise in 2024 to fund our facility expansion, product line extension, R&D and regulatory strategy towards MAA.www.hyjliao.comThe companys goal of offering a regulated ready to use, standardised challenge meal for use in OFCs in any allergologists’ clinics is coming one step closer to reality.â€
About ÎçÒ¹¾ç³¡:
ÎçÒ¹¾ç³¡, established in 2013, operates from a pharmaceutical manufacturing facility in Deeside, North Wales. The GMP facility is licenced to manufacture oral challenge meals, for use in clinical trials, as auxiliary medicinal products. www.hyjliao.comThe ÎçÒ¹¾ç³¡ challenge meals are currently used to diagnose and monitor food allergy in numerous global therapeutic trials. The business is progressing along a strategic path to marketing authorisation. Patents for the challenge meals have been granted in a number of countries.
ÎçÒ¹¾ç³¡ is responding to the rapidly evolving food allergy environment, future plans include expansion into niche areas of food allergen development and manufacture beyond challenge meals.
